title: Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients.
abstract: Based on breast cancer families with multiple and/or early-onset cases, estimates of the lifetime risk of breast cancer in carriers of BRCA1 or BRCA2 mutations may be as high as 85%. The risk for individuals not selected for family history or other risk factors is uncertain. We determined the frequency of the common BRCA1 (185delAG and 5382insC) and BRCA2 (6174delT) mutations in a series of 268 anonymous Ashkenazi Jewish women with breast cancer, regardless of family history or age at onset. DNA was analyzed for the three mutations by allele-specific oligonucleotide hybridization. Eight patients (3.0%, 95% confidence interval [CI] 1.5%-5.8%) were heterozygous for the 185delAG mutation, two (0.75%, 95% CI 0.20-2.7) for the 5382insC mutation, and eight (3.0%, 95% CI 1.5-5.8) for the 6174delT mutation. The lifetime risk for breast cancer in Ashkenazi Jewish carriers of the BRCA1 185delAG or BRCA2 6174delT mutations was calculated to be 36%, approximately three times the overall risk for the general population (relative risk 2.9, 95% CI 1.5-5.8). For the 5382insC mutation, because of the low number of carriers found, further studies are necessary. The results differ markedly from previous estimates based on high-risk breast cancer families and are consistent with lower estimates derived from a recent population-based study in the Baltimore area. Thus, presymptomatic screening and counseling for these common mutations in Ashkenazi Jewish women not selected for family history of breast cancer should be reconsidered until the risk associated with these mutations is firmly established, especially since early diagnostic and preventive-treatment modalities are limited.
authors.affiliation: Department of Human Genetics, The Mount Sinai School of Medicine, New York, NY 10029, USA.
authors.forename: F H
authors.initials: FH
authors.lastname: Fodor
authors.forename: A
authors.initials: A
authors.lastname: Weston
authors.forename: I J
authors.initials: IJ
authors.lastname: Bleiweiss
authors.forename: L D
authors.initials: LD
authors.lastname: McCurdy
authors.forename: M M
authors.initials: MM
authors.lastname: Walsh
authors.forename: P I
authors.initials: PI
authors.lastname: Tartter
authors.forename: S T
authors.initials: ST
authors.lastname: Brower
authors.forename: C M
authors.initials: CM
authors.lastname: Eng
mesh_terms: D000328:Adult; D017668:Age of Onset; D000368:Aged; D000483:Alleles; D024682:BRCA2 Protein; D001943:Breast Neoplasms / Q000453:epidemiology* / Q000208:ethnology; D005260:Female; D005787:Gene Frequency / Q000235:genetics; D019398:Genes, BRCA1 / Q000235:genetics*; D006579:Heterozygote; D006801:Humans; D007585:Jews; D008875:Middle Aged; D009154:Mutation / Q000235:genetics; D009363:Neoplasm Proteins / Q000235:genetics*; D010375:Pedigree; D016133:Polymerase Chain Reaction; D012306:Risk; D014157:Transcription Factors / Q000235:genetics*
chemical_list: D024682:BRCA2 Protein; D009363:Neoplasm Proteins; D014157:Transcription Factors